Literature DB >> 18327208

Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.

Simion Chiosea1, Alyssa Krasinskas, Philip T Cagle, Kisha A Mitchell, Dani S Zander, Sanja Dacic.   

Abstract

Definitive diagnosis of malignant mesothelioma in small specimens can be extremely difficult based on morphology alone. Homozygous deletion of 9p21, the locus harboring the p16 gene, has been reported as the most common genetic alteration in malignant mesotheliomas. Recent studies demonstrated that this alteration may be useful for differentiating benign from malignant mesothelial proliferations in cytology specimens. The aim of this study was to evaluate the diagnostic utility of homozygous deletion of 9p21 assessed by fluorescence in situ hybridization (FISH) in mesothelial proliferations involving serosal surfaces in paraffin-embedded tissue. p16 protein immunoexpression was also explored as a potential diagnostic aid. FISH analysis demonstrated homozygous deletion of the 9p21 locus in 35 of 52 cases (67%) of pleural mesothelioma and in 5 of 20 cases of peritoneal mesothelioma (25%) (P<0.005). None of 40 cases of reactive pleural mesothelial proliferations showed p16 deletion (P<0.005). Loss of immunoexpression of p16 was observed in 71% of the peritoneal mesotheliomas, 40% of the pleural malignant mesotheliomas and 15% of the reactive mesothelial cells. Homozygous deletion did not correlate with p16 protein expression in any of the studied groups. Our study suggests that 9p21 homozygous deletion assessed by FISH on paraffin-embedded tissue may be helpful for differentiating between malignant mesotheliomas and reactive mesothelial proliferations. A discrepancy between p16 protein expression and homozygous deletion suggests that other molecular mechanisms may play a role in p16 protein expression in mesothelial proliferations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327208     DOI: 10.1038/modpathol.2008.45

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  32 in total

1.  Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.

Authors:  Yoshiaki Kinoshita; Makoto Hamasaki; Masayo Yoshimura; Shinji Matsumoto; Akinori Iwasaki; Kazuki Nabeshima
Journal:  Mod Pathol       Date:  2019-06-23       Impact factor: 7.842

Review 2.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

3.  Novel insights and recent discoveries on the genetics and pathogenesis of malignant mesothelioma.

Authors:  Yin P Hung; Lucian R Chirieac
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

4.  Molecular characterization of diffuse malignant peritoneal mesothelioma.

Authors:  Yin P Hung; Fei Dong; Matthew Torre; Christopher P Crum; Raphael Bueno; Lucian R Chirieac
Journal:  Mod Pathol       Date:  2020-06-05       Impact factor: 7.842

Review 5.  [The German Mesothelioma Register : Current pathological diagnostics and services].

Authors:  I S Feder; M Jülich; A Tannapfel; I Tischoff
Journal:  Pathologe       Date:  2018-12       Impact factor: 1.011

6.  DNA copy number gains in malignant pleural mesothelioma.

Authors:  Masashi Furukawa; Shinichi Toyooka; Tatsuro Hayashi; Hiromasa Yamamoto; Nobukazu Fujimoto; Junichi Soh; Shinsuke Hashida; Kazuhiko Shien; Hiroaki Asano; Keisuke Aoe; Kazunori Okabe; Harvey I Pass; Kazunori Tsukuda; Takumi Kishimoto; Shinichiro Miyoshi
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

7.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Authors:  Marta Cigognetti; Silvia Lonardi; Simona Fisogni; Piera Balzarini; Vilma Pellegrini; Andrea Tironi; Luisa Bercich; Mattia Bugatti; Giulio Rossi; Bruno Murer; Mattia Barbareschi; Silvia Giuliani; Alberto Cavazza; Gianpietro Marchetti; William Vermi; Fabio Facchetti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

8.  Primary pleural epithelioid sarcoma of the proximal type: a diagnostic and therapeutic challenge.

Authors:  Zeeshan Ahmad; Qasim Stanazai; Staphanie Wright; Matthew Smolkin; Patrick C Ma
Journal:  Transl Lung Cancer Res       Date:  2019-10

9.  Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.

Authors:  Sanja Dacic; Hannelore Kothmaier; Stephanie Land; Yongli Shuai; Iris Halbwedl; Patrizia Morbini; Bruno Murer; Camilla Comin; Françoise Galateau-Salle; Funda Demirag; Handan Zeren; Richard Attanoos; Alan Gibbs; Philip Cagle; Helmut Popper
Journal:  Virchows Arch       Date:  2008-10-29       Impact factor: 4.064

10.  The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.

Authors:  Aatur D Singhi; Alyssa M Krasinskas; Haroon A Choudry; David L Bartlett; James F Pingpank; Herbert J Zeh; Alyssa Luvison; Kimberly Fuhrer; Nathan Bahary; Raja R Seethala; Sanja Dacic
Journal:  Mod Pathol       Date:  2015-10-23       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.